rising-dose trial indicated that the compound is probably too subtype-specific to provide adequate efficacy. The precise selectivity profile of the compound remains to be determined. This Review ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.